Pityriasis Lichenoides in Childhood: Review of Clinical Presentation and Treatment Options

Pediatr Dermatol. 2015 Sep-Oct;32(5):579-92. doi: 10.1111/pde.12581. Epub 2015 Mar 26.

Abstract

Pityriasis lichenoides (PL) is a skin condition of unclear etiology that occurs not uncommonly in childhood. It is often classified into the acute form, pityriasis lichenoides et varioliformis acuta (PLEVA), and the chronic form, pityriasis lichenoides chronica (PLC). We performed a comprehensive review of the English-language literature using the PubMed database of all cases of childhood PL reported from 1962 to 2014 and summarized the epidemiology, clinical features, treatment options, and prognosis of this condition in children. The proposed etiologies are discussed, including its association with infectious agents, medications, and immunizations and evidence for PL as a lymphoproliferative disorder. We found an average age of PL onset of 6.5 years, with a slight (61%) male predominance. We also found that PLEVA and PLC tend to occur with equal frequency and that, in many cases, there is clinical and histopathologic overlap between the two phenotypes. When systemic therapy is indicated, we propose that oral erythromycin and narrowband ultraviolet B phototherapy should be first-line treatment options for children with PL since they have been shown to be effective and well tolerated. In most cases, PL follows a benign course with no greater risk of cutaneous T-cell lymphoma, although given the rare case reports of transformation, long-term follow-up of these patients is recommended.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Age Factors
  • Biopsy, Needle
  • Child
  • Clindamycin / administration & dosage*
  • Combined Modality Therapy
  • Female
  • Humans
  • Immunohistochemistry
  • Male
  • Pityriasis Lichenoides / diagnosis*
  • Pityriasis Lichenoides / epidemiology
  • Pityriasis Lichenoides / therapy*
  • Prognosis
  • Risk Assessment
  • Severity of Illness Index
  • Sex Factors
  • Treatment Outcome
  • Ultraviolet Therapy / methods*

Substances

  • Clindamycin